Target relapsed or refractory
    multiple myeloma (RRMM) at the cell

    Get to the core
    Get to the core Get to the core

    with XPOVIO® (selinexor)

    The First and Only
    FDA-Approved
    Oral
    Medicine of its Kind

    XPOVIO may work when
    you’ve stopped responding to
    other treatments
    (lenalidomide,
    pomalidomide, bortezomib,
    carfilzomib, and daratumumab).

    See Clinical Trial Outcome

    XPOVIO may work when
    you’ve stopped responding to
    other treatments
    (lenalidomide,
    pomalidomide, bortezomib,
    carfilzomib, and daratumumab).

    What is XPOVIO?

    XPOVIO® (selinexor) is a prescription medicine used:

    • in combination with dexamethasone to treat adults with multiple myeloma (MM) that has come back (relapsed) or that did not respond to previous treatment (refractory), and
      • who have received at least 4 prior therapies, and
      • whose disease did not respond (refractory) to at least 2 proteasome inhibitor medicines, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody medicine

    What is the most important information I should know about XPOVIO?

    Your healthcare provider will do blood tests before you start taking XPOVIO, and often during the first 3 months of treatment, and then as needed during treatment to monitor you for side ef‍fects. Your healthcare provider may change your dose of XPOVIO, stop your treatment for a period of time, or completely stop your treatment if you have certain side ef‍fects during treatment with XPOVIO.